USPTO granted patent US12590083B2 to the University of Virginia Patent Foundation for inhibitors of spinster homolog 2 (SPNS2) for use in therapy. The patent covers compounds according to Formula I, their pharmaceutically acceptable salts, and/or tautomers, along with pharmaceutical compositions and methods of use. The filing date was January 22, 2020, with application number 17310179. The patent contains 2 claims.

Pharmaceutical companies and researchers developing therapies targeting SPNS2 should conduct freedom-to-operate analyses to determine whether licensing is required before commercial development. No immediate compliance deadlines or regulatory submissions are required. Competitors should monitor the patent scope when designing around compounds for conditions including gastrointestinal, metabolic, respiratory, dermatological, oncology, and immunology indications.